Mandate

Vinge advises Litorina IV in connection with acquisition of Gullbergs

July 16, 2012

Vinge has advised Litorina IV L.P., in relation to its acquisition of a majority shareholding in Gullbergs Sverige AB. Gullbergs is the market leader in relation to the supply of office materials to small and medium sized enterprises. The company’s former major shareholders, Anders Bogren and Fredrik Paulsson, will retain significant shareholdings in the company. Gullbergs currently has 21 stores predominantly located in southern Sweden and the Lake Mälaren region which, together with the company’s field sales personnel, customer service and online portal supply goods and services to more than 25 000 customers throughout Sweden. In 2001, the company’s turnover was SEK 515 million. The acquisition is subject to approval by the relevant competition authorities and other customary conditions precedent to closing.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Kristina Ekberg and Louise Markgren. Associate Peter Alstergren provided competition law advice.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026